Previous 10 | Next 10 |
Gainers: [[AKBA]] +8%. [[FATE]] +5%. [[CHMA]] +3.5%. [[UAVS]] +3%. [[ZAGG]] +2%.Losers: [[KLIC]] -5.1%. [[ACRS]] -4.6%. [[LITB]] -2.9%. [[CORR]] -2.6%. [[DPW]] -1.3%. For further details see: CORR, FATE, AKBA and DPW among after-hours movers
Chiasma (CHMA) reports that President and Principal Financial Officer Mark Fitzpatrick intends to step down. He will remain on the job until no later than June 30, 2021 to ensure a smooth transition to his successor. A search is underway. For further details see: Chiasma finance chief t...
NEEDHAM, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to reduce the burden of chronic injections for people with rare diseases, as ev...
NEEDHAM, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to reduce the burden of chronic injections for people with rare diseases, today announced that m...
Crinetics Pharmaceuticals (NASDAQ: CRNX ) announces that a presentation of its orally available small molecule adrenocorticotropic hormone (ACTH) antagonist was selected for a late-breaking session a the virtual European Congress of Endocrinology on September 8. More news on: Crinetics...
Crinetics Pharmaceuticals ( CRNX ) has a lead molecule, paltusotine, that may be best in class. Phase 2 testing is on track to be completed in Q4 2020 and may act as a catalyst for the stock to move up if the data is positive. Peak sales potential for paltusotine, if approved, could reach $1.5...
Chiasma ( CHMA -0.7% ) has launched MYCAPSSA capsules in the United States for patients with acromegaly. More news on: Chiasma, Inc., Healthcare stocks news, Read more ...
NEEDHAM, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to reduce the burden of chronic injections for people with rare diseases, today announced the com...
NEEDHAM, Mass., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to reduce the burden of chronic injections for people with rare diseases, today announced the onl...
Image source: The Motley Fool. Chiasma (NASDAQ: CHMA) Q2 2020 Earnings Call Aug 10, 2020 , 5:00 p.m. ET Operator Continue reading
News, Short Squeeze, Breakout and More Instantly...
Pulmatrix appoints Director Anand Varadan PR Newswire LEXINGTON, Mass. , July 27, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and...
NEEDHAM, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives ...
NEEDHAM, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”) today presented patient-reported outcomes (PROs) data from its MPOWERED™ Phase 3 trial demonstrating that study patients with acromegaly reported si...